Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status

  • Authors:
    • Hyeong Su Kim
    • Jung Han Kim
    • Hee Jun Kim
    • Hyun Joo Jang
    • Jin Bae  Kim
    • Ji Won Kim
    • So Young Jung
    • Byung Chun Kim
    • Dae Hyun Yang
    • Soah  Park
    • Keong Ju Kim
    • Soon Il Lee
    • Dae Young Zang
  • View Affiliations

  • Published online on: November 25, 2011     https://doi.org/10.3892/ol.2011.496
  • Pages: 425-428
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study was designed to retrospectively evaluate the efficacy and safety of modified FOLFOX-6 regimen in advanced gastric cancer (AGC) patients with poor performance status (PS). From January 2005 to August 2010, 23 AGC patients with poor PS who received mFOLFOX-6 as first-line chemotherapy were reviewed. Patients received 100 mg/m2 oxaliplatin and 100 mg/m2 leucovorin (LV) as a 2-h intravenous infusion on day 1, followed by 5-fluorouracil (5-FU) at 2000 mg/m2 as a 46-h continuous infusion. A total of 22 patients received more than 3 cycles of chemotherapy and were evaluable for tumor response. Seven patients achieved partial response, giving an overall response rate of 31.8%. The median time to progression and overall survival were 3.5 and 9.2 months, respectively. Grade 3-4 hematological toxicities were noted: neutropenia in four patients (17.4%), anemia in two (8.7%) and thrombocytopenia in one (4.3%). Two patients developed febrile neutropenia and one of these patients succumbed to sepsis. Grade 3-4 gastrointestinal toxicities, such as nausea, vomiting and diarrhea were observed in less than 10% of patients. Peripheral neuropathy was observed in 9 patients (39.1%). In conclusion, the mFOLFOX-6 regimen for AGC patients with poor PS was effective with acceptable toxicity. Our results suggest that this regimen may be an effective option for these patients.
View Figures
View References

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim H, Kim J, Kim H, Jang H, Kim J, Kim J, Jung S, Kim B, Yang D, Park S, Park S, et al: Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett 3: 425-428, 2012
APA
Kim, H., Kim, J., Kim, H., Jang, H., Kim, J., Kim, J. ... Zang, D. (2012). Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncology Letters, 3, 425-428. https://doi.org/10.3892/ol.2011.496
MLA
Kim, H., Kim, J., Kim, H., Jang, H., Kim, J., Kim, J., Jung, S., Kim, B., Yang, D., Park, S., Kim, K., Lee, S., Zang, D."Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status". Oncology Letters 3.2 (2012): 425-428.
Chicago
Kim, H., Kim, J., Kim, H., Jang, H., Kim, J., Kim, J., Jung, S., Kim, B., Yang, D., Park, S., Kim, K., Lee, S., Zang, D."Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status". Oncology Letters 3, no. 2 (2012): 425-428. https://doi.org/10.3892/ol.2011.496